| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
|
Bai, Longchuan
|
|
2019
|
36 |
5 |
p. 498-511.e17
|
artikel
|
| 2 |
ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures
|
Qadeer, Zulekha A.
|
|
2019
|
36 |
5 |
p. 512-527.e9
|
artikel
|
| 3 |
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
|
Grosser, Rachel
|
|
2019
|
36 |
5 |
p. 471-482
|
artikel
|
| 4 |
Companion Diagnostics to Identify Biomarkers of Response to Anticancer Drugs Targeting the Proteome
|
Joshua, Anthony M.
|
|
2019
|
36 |
5 |
p. 464-465
|
artikel
|
| 5 |
Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy
|
Hopkins, Jessica L.
|
|
2019
|
36 |
5 |
p. 461-463
|
artikel
|
| 6 |
Inhibit versus Destroy: Are PROTAC Degraders the Solution to Targeting STAT3?
|
Heppler, Lisa N.
|
|
2019
|
36 |
5 |
p. 459-461
|
artikel
|
| 7 |
Paradigms for Precision Medicine in Epichaperome Cancer Therapy
|
Pillarsetty, Nagavarakishore
|
|
2019
|
36 |
5 |
p. 559-573.e7
|
artikel
|
| 8 |
Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG
|
Anastas, Jamie N.
|
|
2019
|
36 |
5 |
p. 528-544.e10
|
artikel
|
| 9 |
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
|
Han, Huiying
|
|
2019
|
36 |
5 |
p. 483-497.e15
|
artikel
|
| 10 |
Stressing Out about Cancer Immunotherapy
|
He, Xue-Yan
|
|
2019
|
36 |
5 |
p. 468-470
|
artikel
|
| 11 |
Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer
|
Quereda, Victor
|
|
2019
|
36 |
5 |
p. 545-558.e7
|
artikel
|
| 12 |
Tumor Neoantigens: When Too Much of a Good Thing Is Bad
|
Trinh, Anne
|
|
2019
|
36 |
5 |
p. 466-467
|
artikel
|
Tijdschrift beschrijving